Skip to content

Main Navigation

  • About us
    • Our team
    • Employee stories
    • Working with us
    • Our principles
    • Mission, vision & values
    • History
    • Corporate Social Responsibility
  • Science & Services
    • Contexts of use
      • Trial design and analyses
      • Program strategies and efficiencies
      • Special/specific populations
      • Special considerations
      • Regulatory interactions
    • Pharmetheus Platforms
      • Model-Informed Drug Development
      • PBPK & PBBM
      • Pharmacometrics
      • QSP
    • Solutions
      • Milestone Analysis
      • Embedded Scientist
      • Expert Advice
      • Training workshop
      • Scientific Publication
    • Specific services
      • Model-Informed Bioequivalence & Biosimilarity
    • Publications
    • Case studies
    • Academic collaborations
  • Careers
  • Events
  • News
  • Contact us
  • LinkedIn

A joint ketamine and esketamine exposure-response model of MADRS score in major depressive disorder to enable informed trial design for candidate drugs with similar mode of action

PAGE 30 (2022) Abstr 10060
Faraj A, Kristoffersson A, Desch M, Niebecker R.
CNSConferencePharmacometricsTrial design and analysis

Pharmetheus Affiliates

Portrait-of-Anders-Kristofersson-Pharmetheus
Senior Consultant

Anders Kristoffersson

See bio

Contact

Pharmetheus AB
Kungsängstull 4
753 19 Uppsala, Sweden

Visiting address: Dragarbrunnsgatan 77, 5th floor

info@pharmetheus.com

+46(0)18-51 33 28

Links

  • Home
  • Newsletter
  • LinkedIn
  • Whistleblower
  • Privacy Policy
  • Cookie Policy
  • Consent Preferences

Services

  • Contexts of use
  • Pharmetheus platforms
  • Solutions
  • Case studies
  • Publications

About

Pharmetheus is a consultancy firm helping clients reduce uncertainty in technical and regulatory processes, increasing confidence in the development of new medicines that can improve patients’ lives.